Last reviewed 2026-04-22 · How we verify

Perindopril (T1)

Hospices Civils de Lyon · FDA-approved active Small molecule

Perindopril (T1) is a ACE inhibitor Small molecule drug developed by Hospices Civils de Lyon. It is currently FDA-approved for Hypertension, Heart failure, Post-myocardial infarction.

Perindopril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure.

Perindopril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure. Used for Hypertension, Heart failure, Post-myocardial infarction.

At a glance

Generic name	Perindopril (T1)
Sponsor	Hospices Civils de Lyon
Drug class	ACE inhibitor
Target	Angiotensin-converting enzyme (ACE)
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

ACE inhibitors block the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to vasodilation, reduced aldosterone secretion, and decreased sodium and water retention, resulting in lower blood pressure and reduced cardiac workload. Perindopril is a long-acting ACE inhibitor commonly used in hypertension and heart failure management.

Approved indications

Hypertension
Heart failure
Post-myocardial infarction
Chronic kidney disease

Common side effects

Dry cough
Dizziness
Hyperkalemia
Angioedema
Fatigue
Headache

Key clinical trials

IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Perindopril (T1) CI brief — competitive landscape report
Perindopril (T1) updates RSS · CI watch RSS
Hospices Civils de Lyon portfolio CI

Frequently asked questions about Perindopril (T1)

What is Perindopril (T1)?

Perindopril (T1) is a ACE inhibitor drug developed by Hospices Civils de Lyon, indicated for Hypertension, Heart failure, Post-myocardial infarction.

How does Perindopril (T1) work?

Perindopril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure.

What is Perindopril (T1) used for?

Perindopril (T1) is indicated for Hypertension, Heart failure, Post-myocardial infarction, Chronic kidney disease.

Who makes Perindopril (T1)?

Perindopril (T1) is developed and marketed by Hospices Civils de Lyon (see full Hospices Civils de Lyon pipeline at /company/hospices-civils-de-lyon).

What drug class is Perindopril (T1) in?

Perindopril (T1) belongs to the ACE inhibitor class. See all ACE inhibitor drugs at /class/ace-inhibitor.

What development phase is Perindopril (T1) in?

Perindopril (T1) is FDA-approved (marketed).

What are the side effects of Perindopril (T1)?

Common side effects of Perindopril (T1) include Dry cough, Dizziness, Hyperkalemia, Angioedema, Fatigue, Headache.

What does Perindopril (T1) target?

Perindopril (T1) targets Angiotensin-converting enzyme (ACE) and is a ACE inhibitor.

Drug class: All ACE inhibitor drugs
Target: All drugs targeting Angiotensin-converting enzyme (ACE)
Manufacturer: Hospices Civils de Lyon — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Hypertension
Indication: Drugs for Heart failure
Indication: Drugs for Post-myocardial infarction

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing